I 族和 II 族金属的卤化物或拟卤化物与氨基甲酸酯保护的氮丙啶和氮杂环丁烷在作为溶剂的液体二氧化硫中的反应导致这些杂环的有效开环。二氧化硫作为一种高极性溶剂,可溶解无机盐并充当温和的路易斯酸以加速开环。因此,可以使用氨基甲酸酯保护的小杂环代替相应的磺酰胺,其活性在开环反应中得到很好的证实。硫醇在 SO2 辅助的氮丙啶开环中也表现良好。该过程没有立体中心的外消旋化。
Synthesis and evaluation of N,S-compounds as chiral ligands for transfer hydrogenation of acetophenoneElectronic supplementary information (ESI) available: NMR spectra. See http://www.rsc.org/suppdata/ob/b2/b208907f/
作者:Jenny K. Ekegren、Peter Roth、Klas Källström、Tibor Tarnai、Pher G. Andersson
DOI:10.1039/b208907f
日期:2003.1.13
New nitrogen- and sulfur-containing compounds, bicyclic and monocyclic, were prepared and evaluated as ligands in the transfer hydrogenation of acetophenone. Utilising [Ir(COD)Cl]2 as metal precursor the best result, 80% ee, was obtained using a bicyclic sulfoxide ligand.
[EN] DIAMINOCYCLOHEXANE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE DIAMINOCYCLOHEXANE ET LEURS UTILISATIONS
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2013012829A1
公开(公告)日:2013-01-24
The present invention provides compounds of Formula (I) or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.
Mild metal-free syn-stereoselective ring opening of activated epoxides and aziridines with aryl borates
作者:Mauro Pineschi、Ferruccio Bertolini、Robert M. Haak、Paolo Crotti、Franco Macchia
DOI:10.1039/b416517a
日期:——
A conceptually new, simple and practical method for the syn-nucleophilic displacement of aryl and vinyl epoxides and aryl aziridines with (substituted) phenols, using aryl borates as activating nucleophiles under neutral conditions, is reported.
The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
The present invention provides compounds of Formula (I):
or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are agonists, partial agonists and modulators of the NPY Y4 receptor and may be used for the treatment and prophylaxis of various diseases and conditions.